Sheila Bhave1, Amita Sapru, Ashish Bavdekar, Vaibhavi Kapatkar, Amey Mane. 1. Department of Pediatrics, KEM Hospital Research Centre, Pune; and *Department of Medical Affairs, Wockhardt Limited, Mumbai; India. Correspondence to: Dr Sheila Bhave, Department of Pediatrics, KEM Hospital Research Centre, Rasta Peth, Pune 411 011, India. kemhrc@vsnl.net.
Abstract
OBJECTIVES: To assess immunogenicity of a single dose of live attenuated hepatitis A vaccine in Indian children, ten years after immunization. METHODS: Of 143 children vaccinated in 2004, 121 children were evaluated in 2014, clinically and for anti-HAV antibodies. RESULTS: 13 children were early vaccine failures who received two doses of HAV vaccine subsequently. 106 (98%) of 108 remaining children had seroprotective levels with a geometric mean titer of 100.5 mIU/mL. On analysis of all 121 children, the immunogenicity was 87.6%. CONCLUSION: Single dose of live attenuated hepatitis A vaccine provides long-term immunity in Indian children.
OBJECTIVES: To assess immunogenicity of a single dose of live attenuated hepatitis A vaccine in Indian children, ten years after immunization. METHODS: Of 143 children vaccinated in 2004, 121 children were evaluated in 2014, clinically and for anti-HAV antibodies. RESULTS: 13 children were early vaccine failures who received two doses of HAV vaccine subsequently. 106 (98%) of 108 remaining children had seroprotective levels with a geometric mean titer of 100.5 mIU/mL. On analysis of all 121 children, the immunogenicity was 87.6%. CONCLUSION: Single dose of live attenuated hepatitis A vaccine provides long-term immunity in Indian children.